化疗联合DC-CIK细胞免疫治疗对晚期结直肠癌的临床疗效及免疫功能的影响

摘要

Objective:To investigate the clinical effect of chemotherapy combined with DC -CIK immune therapy on patients with advanced colorectal cancer.Methods:A total of 68 patients with advanced colorectal cancer admitted from April 2013 to January 2016 were randomly divided into study group (n =34,DC-CIK cells combined with FOLFOX scheme chemotherapy) and control group (n =34,FOLFOX scheme chemotherapy only).The immune function,quality of life,clinical efficacy and safety were evaluated and compared between the two groups.Results:After treatment,positive cell rates of CD3 +,CD3 +/CD4 + T lymphocytes,CD3 +/CD8 + T lymphocytes,NK cells,the contents of IFN-γand IL-2 were decreased significantly (P ＜ 0.05),while the content of IL-6 increased significantly in the control group (P＜0.05);in contrast,after treatment,the positive cell rates of CD3+,CD3+/ CD4+ T lymphocytes,CD3+/CD8 + T lymphocytes,NK cells,CIK cells and the contents of IFN-γ and IL-2 were increased significantly in the study group (P ＜ 0.05),which was significantly higher than those in the control group (P ＜0.05).After treatment,the quality of life improvement rate,disease response rate,disease control rate in the study group were 82.35％,58.82％,82.35％,which were significantly higher than those in the control group (P＜ 0.05).The incidence of adverse reactions in the study group was significantly less than that in the control group.Conclusion:DC-CIK cell immunotherapy combined with chemotherapy can significantly improve the clinical efficacy,immune function and life quality of patients with advanced colorectal cancer.%目的:观察晚期结直肠癌患者采用化疗联合树突状细胞(dendritic cells,DC)-细胞因子诱导的杀伤细胞(cytokine induced killer cells,CIK)免疫治疗的临床效果.方法:将我院2013-04～2016-01收治的68例中晚期非小细胞肺癌患者随机分为实验组(n=34,DC-CIK细胞免疫联合FOLFOX方案化疗)和对照组(n=34,FOLFOX方案化疗).评价两组患者治疗前后的免疫功能状态、生活质量、临床疗效及安全性.结果:治疗后,对照组CD3+、CD3 +/CD4+T淋巴细胞、CD3+/CD8+T淋巴细胞、NK细胞的阳性率、IFN-γ、IL-2含量显著降低(P＜0.05),IL-6含量显著增高(P＜0.05);实验组CD3+、CD3 +/CD4+T淋巴细胞、CD3+/CD8+T淋巴细胞、NK细胞、CIK细胞阳性率、IFN-γ、IL-2含量显著升高(P＜0.05),并且显著高于对照组治疗后(P＜0.05).实验组生活质量提高率为82.35％,疾病有效率为58.82％,疾病控制率为82.35％,明显高于对照组(P＜0.05).实验组不良反应的发生率明显低于对照组.结论:DC-CIK细胞免疫治疗联合化疗能够提高晚期结直肠癌患者的临床治疗效果,并且能显著改善患者的免疫功能和生活质量.